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2. Abbreviations and glossary 
ACS  acute coronary syndrome 
AMI  acute myocardial infarction 
AP  angina pectoris 
AP-1  activator protein-1 
CABG  coronary artery bypass graft 
CAM  cellular adhesion molecule 
CCR2  chemokine receptor type 2 
cDNA  complementary DNA 
CK  creatine kinase 
CKMB creatine kinase myocardial band 
COLD  chronic obstructive lung disease 
CV  coefficient of variation 
CVD  cardiovascular disease 
DHA  docosahexaenoic acid 
DNA  deoxyribose nucleotid acid 
ELISA  enzyme linked immunosorbent assays 
EMMPRIN extracellular matrix metalloproteinase inducer (CD147) 
EPA  eicosapentaenoic acid 
GP  glycoprotein 
HDL  high density lipoprotein 
HT  hypertension 
IGF  insulin growth factor 
IL-1  interleukin 1   
IL-6  interleukin 6 
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IL-10  interleukin 10 
LDL  low density lipoprotein 
LVEF  left ventricular ejection fraction 
mBMC bone marrow-derived mononuclear cells 
MCP-1 monocyte-chemoattractant protein-1 
MI  myocardial infarction 
MMP  matrix metalloproteinase 
mRNA messenger ribose nucleotid acid 
MRI  magnetic resonance imaging 
n-3 PUFA n-3 polyunsaturated fatty acids 
NF-NB  nuclear factor-NB 
NSTEMI non ST-elevation myocardial infarction 
oxLDL oxidized low density lipoprotein 
PAPP-A pregnancy associated plasma protein A 
PCI  percutaneous coronary intervention 
PCR  polymerase chain reaction 
RNA  ribose nucleotid acid 
SPECT single photon emission computed tomography 
STEMI ST-elevation myocardial infarction 
TGFE  transforming growth factor E 
TIMP-1 tissue inhibitor of metalloproteinases 1 
TIMP-2 tissue inhibitor of metalloproteinases 2 
TCSF  tumor cell-derived collagenase stimulatory factor  
Th2  T helper cell type 2 
TNFĮ  tumor necrosis factor Į  
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4. Introduction
In developed countries, cardiovascular disease (CVD) is the leading cause of morbidity and 
death (1). Ischemic heart disease is often a late and dreaded complication of atherosclerosis, a 
key process in myocardial infarction (MI) and most strokes (2;3).  
The early and late mortality of AMI is declining. Nevertheless, despite an increasing 
knowledge about risk factors for acute myocardial infarction (AMI) which may lead to 
congestive heart failure or cardiac death, CVD still affects worldwide.  
Inflammation is considered to be an important prosess for development of 
atherosclerosis and this includes a number of cellular and molecular responses resulting in 
plaque formation (2;4). The atherogenesis includes excessive subendothelial lipid 
accumulation in macrophages, which transform into foam cells that further secrete numerous 
of cytokines leading to an inflammatory state.  
 
4.1 Atherosclerosis 
The atherosclerotic lesion (atheroma) is seen as an asymmetric focal thickening of intima, the 
innermost layer of an arterial wall. Accumulation of lipids and components of extracellular 
matrix combined with inflammation, causes atherosclerosis, and early stages are especially 
characterized by subendothelial lipid accumulation. Inflammation is a key process for the 
development of atherosclerosis and is associated with activation of endothelial cells, 
macrophages and T-lymphocytes, and proliferation of smooth muscle cells (2;3).  
Upon stimulation by oxidized LDL the endothelial cells express increased amounts of 
different proinflammatory substances. Different inflammatory cytokines and chemokines play 
central roles in all phases of atherosclerosis from the fatty streaks to advanced atherosclerotic 
plaques (2;3;5) (Figure 1).   
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Figure 1. Adapted from Koenig W, ATVB 2007;27. (8) The developing process of 
atherosclerosis, from fatty streaks to advanced plaques and plaue rupture. 
The endothelium serves as a selective permeable barrier between the vessel wall and the 
circulating blood. Normally it provides a nonthrombogenic and anti-inflammatory surface 
towards circulating blood leukocytes and platelets (6). On the endothelial surface cellular 
adhesion molecules (CAMs), which play a central role in the inflammatory process are 
expressed (7), contributing to adhesion and migration of circulating cells to the intima (8) 
(Figure 2). In the context of monocyte recruitment in the atheroma, the vascular cell adhesion 
molecule 1 (VCAM-1) plays a major role. By adhesion to the activated endothelial layer, the 
monocytes change their phenotype and penetrate into tunica intima. Different chemokines 
contribute in this process, escpecially the interaction between monocyte-chemoattractant 
protein-1 (MCP-1) and its receptor chemokine receptor type 2 (CCR2). Monocytes migrated 
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into the intima get the character of tissue macrophages, express scavenger receptors which 
bind lipoproteins modified by oxidation or glycation, among others.  
 
 
 
 
 
 
 
Figure 2. Adapted from Libby P. Nature. 2002;420:868-74 (8). The transformation process of 
blood monocytes into foam cells, with contribution of chemokines, and migration from 
arterial lumen into the intima.   
 
These processes, as result of accumulation of lipid droplets inside the cytoplasm, create the 
arterial foam cells. Monocyte-derived macrophages and foam cells as well as invaded T-cells, 
involving both the innate and the adaptive immune system have several functions related to 
the development of atherosclerosis and its complications. They secrete pro-inflammatory 
cytokines which enhances the local inflammatory response in the deposit layer (9) 
As the atherosclerotic lesion develops, also smooth muscle cells migrate to the intima in 
response to growth factor released by activated macrophages and endothelial cells. Various 
growth factors in the intima cause smooth muscle cell proliferation and the lesion develops to 
a fibrotic plaque. The smooth muscle cells change their phenotype and become secretory and  
pro-inflammatory (9). 
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 The activated macrophages also play a key role in the thrombotic complications in 
atherosclerosis and plaque rupture, by producing matrix metalloproteinases (MMPs) 
degrading the extracellular matrix which gives strength to the fibrous cap of the plaque (vide 
infra) (10) (Figure  1 and 2). When the plaque ruptures as a consequence of this process, the 
blood comes in contact with other products of the macrophages like the potent pro-coagulant 
protein, tissue factor, the important initiator of the coagulation cascade.  
 
Early activation of endothelial cells may be seen as beneficial due to elimination of 
accumulated lipids by the recruited phagocytizing cells to the intima. In atherosclerosis, 
however, the continous excessive lipid accumulation within the macrophages, transform them 
into lipid rich foam cells that secrete numerous proinflammatory cytokines, leading to a 
chronic low graded inflammatory state. 
 The activation of endothelial cells may occur in response to different stimuli related to 
traditional risk factors for CVD, such as hypercholesterolemia, a diet high in saturated fat, 
lack of physical activity, obesity, hyperglycemia, insulin resistance, hypertension, smoking, 
shear stress and infectious agents. They are all stimuli which mediate migration of monocytes 
and lymphocytes to the intima, thus potentiating the atherosclerotic process (11). 
 
The two major causes of coronary thrombosis are plaque rupture and endothelial 
erosion (6). The immune cells are activated, and they produce numerous inflammatory 
substances and proteolytic enzymes. These, in turn, can transform the plaque into an unstable 
structure that may rupture and induce thrombosis, which may lead to an AMI. The different 
inflammatory mediators play central roles in all phases of the disease (Figure 1). Cytokines 
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like TNFĮ, interleukin-1 (IL-1) and interleukin-6 (IL-6) promote inflammation, whereas 
proteases seem to be of greater importance for plaque destabilization.  
Circulating levels of several pro-inflammatory markers of inflammation have been 
shown to be predictive for cardiovascular events (12-14), of which CRP, IL-6 and IL-18 are 
the most studied markers. On the other hand, activation of the anti-inflammatory cytokines 
like IL-10, TGFE and others are produced from Th2 cells contribute in inhibiting the 
atherosclerotic process and thereby act as “good guys” (7;15).     
 
Although the involvement of inflammation in the development and progression of 
atherosclerosis is undebatable (2), there are still many questions to be answered to recognize 
and define the key players and also to understand the regulatory mechanisms behind. These 
inflammatory players might probably reflect an imbalance between “good and bad guys”.  
4.2. Coronary Heart Disease
Ischemic coronary heart disease refers to failure of coronary circulation to supply adequate 
circulation to cardiac muscle and surrounding tissue, with a reduced oxygen supply and 
thereby an imbalance between oxygen demand and supply. This is most commonly equated 
with atherosclerotic coronary artery disease. It is the most common form of disease affecting 
the heart and is an important cause of premature death in the developed world.  
Angina pectoris (AP) is a clinical syndrome, diagnosis based on clinical and 
laboratory recordings. Symptoms are most common characterized by central retrosternal 
discomfort, but can also be accompanied by radiating pain in arms, shoulder regions, upper 
back, or lower jaw or teeth, or simply dyspnoe. AP is caused by myocardial ischemia as a 
result of an imbalance between myocardial oxygen demand and supply, most often caused by 
atherosclerosis and reduced arterial luminal area. The reduced blood flow causes symptoms 
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especially during physical activity or emotional stress when the demand of oxygen rich blood 
is increased. The pain caused by ischemic myocardium is mediated by stimulation of 
angiotensin I receptors on cardiac nerve endings. The discomfort will typically be relieved by 
rest and/or use of nitroglycerine. 
Acute myocardial infarction (AMI) is caused by ischemia, usually due to formation of 
an occlusive thrombus in a coronary artery and thereby cell death in the myocardium (16). 
The AMI can be visualized and diagnosed by ECG: ST-elevation myocardial infarction 
(STEMI) may indicate an occlusive thrombus in a central artery with indication for prompt 
revascularization by either acute percutaneous coronary intervention (PCI) or thrombolysis. 
Patients with chest pain without ST-elevation in the ECG; Non-ST-elevation myocardial 
infarction (NSTEMI) are normally treated with anti-ischemic and anti-thrombotic therapy 
often followed with coronary angiography later on.  
 
4.3. Metalloproteinases 
4.3.1. In general 
Matrix metalloproteinases (MMPs), initially described in 1962 by Gross et. al (17), are 
proteinases that participate in extracellular matrix degradation through regulation of their 
transcription, activation of the precursor zymogens, interaction with extracellular matrix 
components and inhibition by endogenous inhibitors, TIMPs (18). Metalloproteinases are a 
class of at least 25 zinc-dependent endopeptidases (collagenases, gelatinases, stromelysins 
and membrane type MMPs), and are found in most tissues (19). They are physiological 
regulators of the extracellular matrix, and participate in vascular remodeling, plaque 
instability by degrading the fibrous cap (vide supra), and ventricular remodeling after cardiac 
injury (4;20).  
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4.3.2. Metalloproteinase 9 / Tissue inhibitor of metalloproteinase-1 and -2 
MMP-9, also named gelatinase B (Figure 3) (18), belongs to the group of metalloproteinases 
called gelatinases which means that their substrate is denatured collagens, gelatins (21). These 
enzymes have three repeats of a type II fibronectin domain inserted in the catalytic domain, 
which bind to gelatin, collagens and laminin. In humans the gene for MMP-9 is found on the 
chromosome 20q11.2-q13.1 (18).  
 
 
Figure 3. The strucure of MMP-9 (18). 
 
The structure of the MMP-9 prodomain consists of three Į-helices and connecting loops 
where the first loop between helix 1 and 2 is a protease-sensitive region, and with a cleft of 
catalytic domain containing zinc as the active site.  
Most MMPs, including MM-9, can be activated by cytokines, proteinases, nitrogen oxide 
(NO), heat, low pH and by various chemical agents and growth factors in vitro (4;20-24). 
Most proMMPs are secreted from cells and activated extracellularly (18), and all vascular 
cells including endothelial cells and macrophages secrete MMPs. The regulation of the MMPs 
activation includes genetic regulation, secretion of pro-enzymes that require activation, and 
inhibition by tissue inhibitor of metalloproteinases (TIMPs) (25). In a stepwise activation 
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mechanism it has been shown that proMMP-9, mostly secreted from cells, can be activated 
extracellularely by plasmin, and the zinc-containing site (also called hemopexin) binds to the 
C-terminal of tissue inhibitor of metalloproteinase 1 (TIMP-1). In addition, several MMPs can 
contribute to activation of other MMPs, also MMP-9, in a positive feedback mechanism (23).  
In atherosclerotic vascular tissue MMP-9 is localized at the shoulder of the plaque. This area 
is known to be most vulnerable to plaque rupture. It is reported that the activity of MMP-9 
differ at various stages of plaque progression (25). The role in atherosclerosis is however still 
not fully understood. The MMP-9 is regulated by specific endogenous inhibitors (TIMPs), by 
transcription and by certain precursors, i.e when pro-MMP-9 binds to TIMP-1 (23). The ratio 
between MMP-9 and TIMP-1 may thus be of importance. TIMP-1 is secreted as a soluble 
protein, and its activity is associated with inflammatory cytokines (26). Tissue inhibitor of 
metalloproteinase 2 (TIMP-2) is also a member of the TIMP gene family and a natural 
inhibitor of metalloproteinases. In addition, it plays a unique role in its ability to directly 
suppress the proliferation of endothelial cells, and might therefore be critical to the 
maintenance of tissue homeostasis (27).
4.3.3. EMMPRIN 
Extracellular matrix metalloproteinase inducer (EMMPRIN, CD147), which is a member of 
the immunoglobulin superfamily, has lately been discussed to be involved in both expression 
and release of MMP-9 (29), and may therefore play a regulatory role in atherosclerosis, 
plaque rupture and CVD. EMMPRIN was originally discovered on the surface of solid tumor 
cells (30) and therefore named tumor cell-derived collagenase stimulatory factor (TCSF). 
Later, it has also been shown to be expressed in atherosclerotic plaques as well as in cell types 
like monocytes, macrophages and platelets (31-35). With the ability to induce expression of  
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various matrix metalloproteinases it was renamed EMMPRIN. The structure of EMMPRIN 
consists of two extracellular domains including three glycosylation sites, a transmembrane 
and a short cytoplasmatic domain as shown in Figure 4 (36). The stimulation of MMPs 
depends on the glycosylation state of these sites, because unglycosylated EMMPRIN is 
unable to stimulate MMP induction (37). This site where EMMPRIN binds to the platelet-
specific collagen receptor glycoprotein (GP) VI, is expressed in various cell types, including 
leukocytes and platelets (38). With subsequent activation of MMP-9 it may contribute to 
plaque instability in human atherosclerosis and may therefore be important in events like 
acute coronary syndrome (ACS) and AMI (39-41). Circulating levels of EMMPRIN are 
limited explored in humans. 
 
 
Figure 4. The structure of EMMPRIN (36). 
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4.3.4. Pregnancy-associated plasma protein A
Pregnancy-associated plasma protein A (PAPP-A) was first recognized in pregnant women as 
a high-molecular weight constituent associated with Down syndrome. More recently it has 
been shown that PAPP-A also is present in unstable carotid and coronary atherosclerotic 
plaques and with increased circulating concentrations in individuals with ACS (42). The 
molecular composition in the two different organs are different. Whereas PAPP-A in 
pregnancy exists as a heterotetrameric complex with the proform of eosinophil major basic 
protein, PAPP-A in coronary syndromes has been found to be a protease specific for insulin-
like growth factor-binding protein 4 and –5 (43). In a variety of biological systems, insulin 
growth factor-I (IGF-I) and –II play important roles in promoting cell differentiation and 
proliferation. Therefore, increased bioavailability of IGFs through PAPP-A-mediated 
proteolysis could play a crucial role in the progression of coronary atherosclerosis and thus 
also as a prognostic factor in patients with unstable coronary artery disease (44).  
PAPP-A, as a glycoprotein and an insuline-like growth factor metalloproteinase (4), is 
produced by different cell types, including fibroblasts and vascular smooth muscle cells. 
PAPP-A is disrupting the integrity of the protective cap in the atheroma, and release of PAPP-
A occurs during atherosclerotic plaque disruption (45). Thus, PAPP-A is regarded as 
proatherosclerotic and may therefore play an important role in AMI. (45;46). The exact 
mechanism of PAPP-A in atherosclerosis is, however, not ruled out.  
 
The relationship between MMP-9, TIMP-1, EMMPRIN and PAPP-A and the pathogenesis of 
different phases of atherosclerosis and CHD are still not known in details. Evaluation of the 
circulating levels as well as gene regulatory studies, may contribute to further understanding 
their interactions and role in cardiovascular risk.
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4.4. Interventions
4.4.1. Diet and omega-3 fatty acids 
From epidemiological and clinical studies the importance of certain dietary patterns with 
regard to cardiovascular disease seems obvious.  Especially, dietary fat and fatty acids which 
affect plasma lipids and lipoproteins and thus are linked to atherosclerosis, are of importance. 
Several large observational studies have focused on ‘the Mediterranean diet’ with increased 
intake of fruit, vegetables, fish and cereals, and reduced amounts of saturated fat (47). The 
results of this dietary pattern have shown to reduce all-cause mortality from coronary heart 
disease (48;49).
Polyunsaturated fatty acids (PUFA) are fatty acids containing two or more double bonds and 
classified as n-3 fatty acids (n-3 PUFA) and n-6 fatty acids depending of the localization of 
the first double bond from the methyl end of the molecule. Usually, diet contains both acids, 
dependent of the diet composition. The most common n-6 fatty acid is arachidonic acid which 
metabolize to prostaglandins, leukotrienes and other lipoxygenase or cyclooxygenase 
products, and thereby function as proinflammatory, atherogenic and pro-thrombotic 
substituents (50). In contrast, the typical marine n-3 fatty acids like docosahexaenoic acid 
(DHA) and eicosapentaenoic acid (EPA) (used in the DOIT study) (vide infra) are 
competitive for the arachidonic acid metabolism. 
The clinical benefits of n-3 PUFA of marine origin are well recognized (51). The exact 
mechanism by which n-3 PUFAs exert their cardioprotective effect is, however, still not fully 
understood.  In addition to substantial reduction in serum triglyceride level, they have been 
shown to be antithrombogenic, antiarrhythmic, antiinflammatory and also to improve 
endothelial dysfunction (51). 
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4.4.2. Percutaneous coronary interventions  (PCI)  
Coronary arteries with occlusion or significant stenosis with lumen diameter reduction of  
> 50% are dilated with a transluminal balloon catheter to regain normal blood flow (via 
arteria radialis or arteria femoralis). The earliest methods used plain balloon angioplasty. Bare 
metal stents or drug eluting stents as appropriate, are now in most cases implanted during the 
PCI procedure. Several studies have shown that stent implantation prevent arterial recoil and 
restenosis and thereby reduce the need for repeated revascularization (52).  
 
4.4.3. Autologous bone marrow stem cell transplantation 
Despite well documented treatment of AMI survivors, both medicationally and by PCI, some 
patients either don’t receive this treatment, don’t respond satisfactory, or develop congestive 
heart failure despite treatment.  
Several studies have shown that bone marrow stem cells trans differentiate to cardiomyocytes 
when infused into the affected myocardium (53;54), and paracrine mechanism is one of the 
methods (55). Treatment with autologous stem cells from bone marrow has been suggested to 
reduce myocardial damage in patients with AMI. Results from clinical trials are, however, 
conflicting with regard to improvement of left ventricular ejection fraction (56-62) in patients 
with ST elevation myocardial infarction (STEMI). Possible mechanisms by which autologous 
bone marrow stem cells act are discussed to be cardiac transdifferentiation, paracrine effects, 
angiogenesis, and reduced apoptosis.  
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5. Aims of the study 
The overall aim of the present investigation was to explore any importance of circulating 
levels of MMP-9, TIMP-1 and -2, EMMPRIN and PAPP-A in atherosclerosis and ischemic 
coronary heart disease. 
Specific aims were: 
- to study MMP-9, TIMP-1 and -2 and PAPP-A in a cohort of patients at high risk for 
CHD as related to different disease entities and risk factors in the population (Paper I) 
- to study the effects of diet and/or n-3 PUFA intervention for 3 years on these markers 
(Paper I) 
- to study MMP-9 and TIMP-1 as predictors of clinical cardiovascular outcome in the 
same population (Paper II) 
- to study the time profile of circulating MMP-9, TIMP-1 and -2, and PAPP-A in 
patients with acute STEMI, revascularized with PCI and stent implantation as 
compared to patients with stable angina, electively treated with the same PCI 
procedure (Paper III). 
- to evaluate the influence of intracoronary injections of mBMC on selected 
metalloproteinases in patients with STEMI undergoing PCI. Circulating levels as well 
as genetic expression in circulating leukocytes at different time points were evaluated 
(Paper IV). 
- to investigate any association between the measured proteinases and infarct size 
assessed by myocardial biomarkers and imaging methods like MRI (Paper III) and 
SPECT (Paper IV) (method description; vide infra). 
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6. Materials and methods 
6.1. Study subjects and design 
6.1.1. The Diet and Omega-3 Intervention Trial (DOIT) –study
(Paper I and II) 
The basis for recruitment into the DOIT study was a long term follow-up of the participants 
from the diet- and anti-smoking part of the Oslo study, comprising 1232 men (born 1923-
1932) with high risk of CVD (63). 
Subjects in this cohort were originally included in 1972 if they had serum cholesterol 
concentrations of 6.9-9 mmol/L and systolic blood pressure < 150 mmHg. 
In 1997 the 910 survivors were contacted to participate in the DOIT study (64). Altogether 
655 subjects attended a screening visit, and 563 were enrolled in the final DOIT-study. The 
study has a 2x2 factorial design, and the participants were randomly assigned to receive n-3 
PUFA placebo capsules (corn oil) and no dietary advice (control group); dietary advice and n-
3 PUFA placebo capsules; no dietary advice and n-3 PUFA capsules; and finally dietary 
advice and n-3 PUFA capsules combined (Figure 5).   
 
 
 
 
 
 
Randomization
n=563
Baseline            36 mndr
n-3 PUFA
placebo  +  Diet
placebo
n-3 PUFA + Diet
Figure 5. DOIT study design.  
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Definitions of clinical sub-groups and end-points 
CVD at inclusion was defined as patient history of myocardial infarction, performed PCI, 
coronary artery bypass graft (CABG), aortic dissection, cerebral infarction or claudicatio 
intermittens (all according to hospital records). Diabetes was defined as treated diabetes or 
fasting glucose > 7 mmol/L, and hypertension as treated hypertension and/or systolic/diastolic 
blood pressure >140 / >90 mmHg. 
Cardiovascular events, recorded after 3 years, were a composite of fatal and nonfatal CVD, 
defined as myocardial infarction, revascularization procedures, aortic aneurism, peripheral 
arterial occlusive disease and cerebrovascular events, according to medical records and the 
official death certificates held by Statistics Norway. 
 
6.1.2. Profile of inflammatory markers in acute myocardial infarction:  
          The PIMI trial (Paper III) 
The study design is described in details in Paper III. In brief; it comprises men and women 
between 30 and 75 years with acute ST-elevation myocardial infarction (n = 20) or stable 
angina pectoris (n = 10) admitted to Ullevaal University Hospital, Oslo, Norway. All were 
treated successfully with PCI in a central coronary artery obtaining normal blood flow. 
Patients in the stable angina pectoris (AP) group should have symptoms consistent with stable 
AP and angiographically proven coronary artery disease with indication for PCI. Exclusion 
criteria in both groups were previous transmural infarction, cardiogenic shock and 
considerable co-morbidity (malignancy, stroke, inflammatory diseases, endocrinological 
disturbances and lung disorders). The blood sampling procedure is shown in Figure 6. 
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AMI-group: n=20                               Angina pectoris group: n=10
 
Figure 6. PIMI blood sampling procedure. 
6.1.3. Autologous stem cell transplantation in acute myocardial infarction: 
         The ASTAMI trial (Paper IV) 
The ASTAMI study is decribed in details elsewhere (65). It was a randomized open-labelled 
two-arm study, where one arm was intracoronary treatment with mBMC and the other 
controls. This was performed as a permuted block randomization stratified in two centers, 
Rikshospitalet University Hospital and Ullevål University Hospital, Oslo, Norway.  
One hundred patients, both gender were included.  
Baseline recordings were performed during day 5-7 after AMI, whereas MRI was performed 
after 2-3 weeks and after 6 months.  
Inclusion criteria: 
 - Age between 40 and 75 years 
 - Acute anterior wall myocardial infarction with a history > 3 hours and < 12 hours 
 - ST elevation myocardial infarction (WHO ECG criteria) 
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- Angiographic criteria: occlusion of proximal LAD (ie proximal to second diagonal 
branch) 
- Successful primary rescue PCI (TIMI flow 2 or better) 
- Echocardiographic criteria: Evidence for anterior wall infarction as judged by hypo- 
or akinesia in more than 2 adjacent anterior wall segments (66) 
- Enzymatic criteria: CKMBmass > 3 times upper normal value 
Exclusion criteria: 
 - Previous myocardial infarction with established significant Q waves on ECG 
 - Cardiogenic shock 
 - Hemodynamic instability neccessitating intraarterial baloon pump treatment 
 - Permanent pacemaker or other contraindications to MRI 
 - Stroke with significant sequelae 
- Short life expectancy due to extra cardiac reason, ie. COLD, dissaminated malignant 
disease, or other reason 
 - Uncontrolled endocrinological disturbance 
 - Anamnestic indications for significant mental disorder, including dementia 
 - Established HIV or hepatitis B positivity 
 - Any condition which interfers with patients possibility to comply with protocol 
 
The ASTAMI blood sampling procedure is shown in Figure 7 and described in chapter 6.4. 
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3 months after  AMI2-3 weeks after AMIDay+11Day 0
Baseline 
Day-1AMI
4-5 days
Day+3
Blood samples
 
 
 
 
 
 
 
 
 
 
Figure 7. ASTAMI blood sample procedure. SPECT was performed in addition at day 4-5.  
6.2. Ethics 
The DOIT, PIMI and ASTAMI study protocols, including the biobanks were approved by the 
Regional Committee for Medical Research Ethics and all patients gave written, informed 
consent to participate. The DOIT and ASTAMI studies are registered at 
www.clinicaltrials.gov, NCT number 00764010 (DOIT) and NCT 00199823 (ASTAMI).
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6.3. Interventions 
6.3.1. Diet and omega-3 fatty acids 
Details of the intervention are given in Paper I. Briefly, the dietary advice was individually 
given by a clinical nutritionist, based on a food frequency questionnaire. The subjects were 
supported with a margarine rich in polyunsaturated fatty acids (based on sunflower and 
rapeseed oil) and vegetable oils (rapeseed oil), free of cost.  In addition, to decrease the use of 
meat, advices to increase intake of vegetables, fruit and fish, targeting at energy percents from 
fat 27-30 %, protein 15-18 % and carbohydrate 50-55 % (a “Mediterranean type” diet), were 
given.  The n-3 PUFA capsules (Pikasol, Lube, Denmark) used, contain about 60 % n-3 
PUFA, mainly eicosapentaenoic acid (20:5) and docosahexaenoic acid (22:6) in a ratio 2:1, 
and 3.4 mg/g tocopherols to avoid peroxidation in the capsules.  The placebo capsules (corn 
oil) contain 56 % linoleic acid (18:2 n-6), 32 % oleic acid (18:1 n-9), 10 % palmitic acid 
(16:0) and 3.0 mg/g tochopherols.  Two capsules twice daily, corresponding to a daily intake 
of either 2.4 g n-3 PUFA or 2.4 g corn oil, were given. 
6.3.2 PCI 
The percutaneous coronary intervention with stent implantations of choice as appropriate 
according to patient situation was preformed according to routine procedures in our hospital, 
as was also use of medication per- and post procedure. 
6.3.3. Stem cell transplantation 
The patients were treated in accordance with current guidelines (67) and were randomized 1:1 
to receive mBMC or to a control group. Only the mBMC group was aspirated for 50 ml of 
bone marrow from the iliac crest  4-7 days (baseline) after the acute PCI. The bone marrow 
was treated as previously described in details (65). The next day, a median of 5 days 
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(interquartile range 5 to 6) after AMI (Day 0), 10 ml of the mBMC suspension was injected in 
the infarct related coronary artery. The control group was treated with PCI with stent in the 
infarct related coronary artery at admission, but was not aspirated for bone marrow and did 
not go through any further coronary intervention.  Blood sample procedure is shown in Figure 
7. 
 
6.4. Laboratory methods 
Details on the laboratory measures used are given in each paper. Briefly: 
6.4.1. Blood collection 
In the DOIT-study blood samples were drawn between 8 and 10 am after an overnight fasting 
(10 hours) at the time of randomization (baseline) and after 3 years intervention.  
In the PIMI-study blood samples were collected immediately before PCI in the AP 
group, and 3 and 12 hours, 1, 3, 5, 7 and 14 days after PCI in both groups (Figure 6). From 
day 1 all samples were obtained in fasting state and before intake of any medication.  
In the ASTAMI-study blood samples were collected in fasting condition between 
08.00 and 10.00 am the day before transplantation in the mBMC group (day-1), the day after 
(day 1) and further day 3, and after 2-3 weeks and 3 months (Figure 7). The same time 
interval was used for the control group, except baseline sampling (day-1) which was drawn 
median 4 days after PCI compared to median 5 days in the mBMC group. 
All blood samples, except for routine analyses, were processed and kept frozen at -80°C in a 
biobank until analysed. PaxGene tubes for gene expression in circulating leukocytes were also 
collected, kept at room temperature for at least two hours before freezing.   
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  6.4.2. Enzyme immunoassays 
For analyses of MMP-9, TIMP-1, PAPP-A and EMMPRIN commersial enzyme linked 
immunosorbent assays (ELISA) were used on serum samples. 
For analyses of MMP-9, TIMP-1 and EMMPRIN kits from R&D Systems Europe (Abingdon, 
Oxford, UK) and for PAPP-A kits from DRG Instruments GmBH (Germany) were used. The 
interassay coefficients of variation (CV) were  7.4 % for MMP-9, 4.4 % for TIMP-1, 8.7 % 
for TIMP-2, 5.4 % for EMMPRIN and 6.9 % for PAPP-A.    
 
  6.4.3. RNA isolation and gene expression 
Isolation of RNA from PaxGene tubes was performed according to the manufacturers 
instruction (PreAnalytix, Qiagen GmbH, Germany). The quality and quantity were evaluated 
by use of NanoDrop 1000 (Saveen Werner, Stockholm, Sweden). The procedure is described 
in details in Paper IV. Briefly, the mRNA content was achieved by inversely transcribing total 
RNA in the samples. The genetic expression of the variables was performed by use of real-
time PCR on the ViiATM 7 Real Time PCR System (Applied Biosystems, Foster City, CA, 
USA) and quantified in a relative manner (the ''Ct method (68)). ȕ-2 macroglobulin was 
chosen as house-keeping gene.  
To analyze mRNA expression derived from the PaxGene tubes, reverse transcription (RT) 
followed by polymerase chain reaction (PCR) was used. The mathematical model is described 
by Pfaffl (69). 
 
6.4.4. Ultrasonography 
Intima media thickness (IMT) measurements were used to determine the anatomical structural 
changes in the carotid artery and was performed in a supine position with an ultrasound 
scanner (Acuson 128, Mountain View, CA, USA) with a 7.0 MHz linear array transducer as 
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described in Paper I. All scans were performed by the same sonographer and the ultrasound 
images were captured and recorded on video tapes for off-line analyses.  The analyses were 
performed by experienced personnel (the Ultrasound Laboratory, Clinical research unit, 
Department of Medicine, Malmø University Hospital, Sweden), according to the leading edge 
principle, using a computer assisted image analyzing system. At the position of the thickest 
part in a 10 mm long segment of the far wall of the common carotid artery (CCA) (visually 
judged), three end-diastolic images were obtained. The mean IMT value was used for 
statistical analyses. 
 
6.4.5. Magnetic Resonance Imaging and SPECT 
Cardiac magnetic resonance imaging (MRI) was provided 6 weeks after PCI in the AMI-
group in the PIMI-study using a 1.5 T whole body scanner (Philips Intera, Best, The 
Netherlands) (Paper III). The analysis was performed on View Forum workstation (Philips 
Medical Systems). Short axis images were aquired for left ventricular volume and ejection 
fraction analyses. Infarct size by MRI was determined with the gadolinium late contrast 
enhancement technique (70).  
Single photon emission computed tomography (SPECT) (GE Medical Systems with 4D-
MSPECT software) was used to determine left ventricular ejection fraction (LVEF) and 
infarct size in the ASTAMI trial (Paper IV). Infarct size was expressed as percentage of the 
LAD-area. 
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6.5. Statistics 
Details on statistical analyses used are given in each paper.  
MMP-9, TIMP-1/-2, PAPP-A and EMMPRIN levels were all skewly distributed and non-
parametric statistics were therefore used throughout. Median values and 25, 75 percentiles are 
given, except for baseline characteristis in Paper I and IV. For group comparisons the Mann-
Whitney test was used for continous data, and Chi square test was used for categorial data. 
Friedman test was performed to analyze for differences between any time points within 
groups. For changes within groups (Paper I, III and IV) Wilcoxon test was used, only when 
Friedman test was significant. Multiple linear regression models were used to adjust for 
covariates on logtransformed data when appropriate (Paper I and II). Spearman’s rho was 
calculated for correlation analysis. The SPSS software package version 14.0-18.0 was used 
throughout. 
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7. Summary of results  
7.1. Paper I 
In the DOIT-study, a population at high risk for atherosclerosis and CHD (n = 563), results 
cross sectionally at baseline showed that smokers had significantly higher levels of MMP-9 (p 
< 0.0001) and MMP-9/TIMP-1 ratio (p < 0.0001). TIMP-1 levels were lower in subjects with 
previous AMI (n = 101) (p = 0.021). MMP-9 was significantly correlated to LDL-cholesterol 
and inversely correlated to high density lipoprotein cholesterol (HDL-C) (both p < 0.0001). 
There were no significant correlations between the measured variables and IMT.  
Dietary- and/or n-3 PUFA intervention did not influence the measured markers. Significant 
reductions in the levels of MMP-9 and PAPP-A after 36 months intervention were, however, 
found in all study groups (p<0.0001, all). 
 
7.2. Paper II 
In the DOIT-study, cardiovascular (CV) events were recorded in 68 individuals. Higher levels 
of MMP-9 (p = 0.046) but not triglycerides, total cholesterol, HDL, LDL or oxidised LDL 
were associated with CV events. Univariate regression analysis revealed a significant 
association between higher MMP-9 levels (> 75th percentile; 543 ng/ml) and CV events (OR 
1.93; CI 1.13-2.30; p = 0.016). Analysing MMP-9 combined with lipid levels, it appeared that 
elevated MMP-9 levels predicted CV events significantly in individuals with 
hypertriglyceridaemia (>1.7 mmol/l) (OR 3.69; CI 1.67-8.19; p = 0.001). The prediction of 
CV events by MMP-9 was still significant in patients with hypertriglyceridaemia after 
adjustment for relevant covariates (OR 3.17; CI 1.33 - 7.55; p = 0.009).  
 
 
 
 38
7.3. Paper III 
We investigated the profile of MMP-9, TIMP-1, TIMP-2 and PAPP-A after PCI in patients 
with AMI and stable angina pectoris (AP). In AMI patients (n = 20) levels of MMP-9 and the 
MMP-9/TIMP-1 ratio decreased significantly 1 day after PCI (p < 0.01 for both), sustaining 
during 14 days. Both were higher compared to the AP group (n = 10) at 3 hours (p=0.062 and 
p<0.01, respectively). A similar pattern was observed in PAPP-A levels being significantly 
reduced after 12 hours (p < 0.01). TIMP-1 levels increased significantly after 12 hours (p < 
0.001), sustaining thereafter.  
In the AP group only small changes after PCI were observed, except from a significant 
increase in PAPP-A levels from before PCI to 3 hours (p < 0.0001), followed by significant 
reduction.  
No significant correlations were found between any of the measured biomarkers and the 
infarct size, either evaluated in the acute phase or after 6 weeks. 
 
7.4. Paper IV 
We observed no differences in MMP-9, TIMP-1 or EMMPRIN between the mBMC group 
and the control group during the study period. There was a significantly more pronounced 
increase in MMP-9 from before stem cell transplantation (baseline) to 2-3 weeks (p = 0.03) 
and 3 months (p = 0.05), compared to the control group. EMMPRIN levels were significantly 
reduced from baseline to 2-3 weeks and 3 months in both the mBMC group and the control 
group (p < 0.0001, all), with no difference in changes between the groups. We observed no 
changes in TIMP-1 levels in either groups.  
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MMP-9 and EMMPRIN gene expression levels were significantly reduced from baseline to 3 
months in the mBMC group (p < 0.0001 and p = 0.002 respectively). This could not be 
demonstrated in the control group.  
When defining baseline mRNA level (RQ-values) in the total population to 100 %, there was 
a 20 % reduction in MMP-9 gene expression from baseline to 2-3 weeks, and a 50 % 
reduction after 3 months in the mBMC group. A similar pattern was seen for EMMPRIN, 
with a 20 % reduction after 2-3 weeks and 60 % reduction after 3 months in the mBMC 
group. 
We observed a significant correlation between MMP-9 and EMMPRIN (p = 0.011) at 
baseline. Peak levels of CK correlated significantly to both MMP-9 and EMMPRIN (p = 
0.005 and p < 0.001, respectively). MMP-9 and EMMPRIN were significantly correlated to 
infarct size measured by SPECT (p = 0.018 and p = 0.008 respectively), and EMMPRIN was 
inversely correlated to LVEF at baseline (p = 0.002).  
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8. Discussion 
 8.1. Methodologic considerations 
The DOIT study was an extension of the Oslo Diet and Anti-smoking study from 1972, with a 
predefined population of caucasian male subjects. This is a quite homogenous population of 
long time survivors from a high-risk cohort, and survivor bias coud be a possibility that 
should be taken into account. 
In this study the follow up time frame was three years, which results in longer storage time in 
the freezer for the earliest blood samples collected than the latest. This could influence the 
results of the analyses. However, tests (unpublished data) have shown that some relevant 
markers are stable at -80qC for a longer period, thus we assume no such influence on the 
results. Anyway, between group differences in the intervention trial would not have been 
influenced by the storage time. 
 In the PIMI study we did not manage to collect blood samples before PCI in the AMI 
group as the subjects were acutely admitted to the hospital. We therefore have no information 
about the levels of the measured biomarkers during the first early period of the acute phase. 
The number of patients enrolled were rather limited, thus we cannot rule out statistical type II 
errors. Another limitation is that the included patients in this study had rather small 
myocardial infarcts, and a more profound expression of the measured variables might be seen 
with larger infarcts. 
 In the ASTAMI study bone marrow aspiration and placebo injection was not 
performed in the control group due to ethical reasons. Although baseline characteristics did 
not differ between the goups, these procedures are considered traumatic, and might therefore 
influence the outcome of some of the variables. Furthermore, gene expression of the selected 
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variables was performed in circulating leukocytes, which might not be the main source of 
proteases in the current disease state. 
 The biomarkers used for measurement of infarct size were CK and CK-MB. The 
reason for not using troponin, was that the two hospitals including patients in the ASTAMI 
study (Rikshospitalet University Hospital and Ullevål University Hospital) were using 
different types as standard biomarker, troponin I and troponin T, respectively, and thereby 
complicating the statistics. 
8.2. Association between the measured variables and disease entities
MMP-9 and TIMP-1 were both partly associated with traditional risk factors, significantly 
correlated to LDL-C, inversely to HDL-C, but not to triglycerides. We are not aware of other 
reports on such associations, although Nakamura et al. (71) showed no correlations between 
LDL-C and MMP-9 and TIMP-1 levels in their smaller population of patients with type 2 
diabetes. More recent research, both gene expression studies (72) and on circulating levels 
(73;74) has contributed to the assumption that higher levels of MMP-9 and/or lower levels of 
TIMP-1 is associated with LDL cholesterol.  
Conflicting data regarding the expression pattern of the vascular MMP/TIMP system in 
human hypertension have been reported (75;76). Associations between hypertension and 
elevated levels of MMP-9 have been shown and also a reduction in MMP-9 levels after 
treatment of hypertensives (28;77-79), and also a reduction in blood pressure after inhibiting 
MMP-9 (80;81). For TIMP-1 levels, both increased and decreased levels have been reported 
(28;82;83). In our study population, no association between hypertension and MMPs were 
observed which might be due to the fact that about 30 % of the cohort already was treated for 
their hypertension. A slight inverse correlation between PAPP-A and SBP was recorded, 
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however, not significant after adjustment for covariates. To our knowledge, results on this 
item have not been reported elsewhere. 
No significant differences in MMP-9 or TIMP-1 in diabetics, mostly type 2 diabetes, versus 
non-diabetic subjects, were observed. This is partly in line with the study by Lee et al. (84) 
showing no difference in MMP-9. They could, however, demonstrate significantly higher 
levels of TIMP-1 in type 2 diabetics. Our group have recently also shown in a larger study of 
stable CAD patients no differences in MMP-9 or TIMP-1 in diabetics (type 2) vs non-
diabetics (85).
 It has, however, been shown that type 1 diabetic subjects exhibit significantly higher 
circulating levels of both MMP-9 and MMP-9/TIMP-1 ratio (19). The latter fits in with the 
observation that high glucose has been shown to induce expression and activity of MMP-9 
from monocyte-derived macrophages without affecting TIMP-1 expression (24).  
 
The smokers had significantly higher levels of MMP-9 and MMP-9/TIMP-1 ratio compared 
to the non-smokers. This difference was still significant after adjusting for covariates. A 
stimulating effect of smoking on MMP-9 secretion has been shown in mice (86) and also in 
cultures of human endothelial cells (87). This observation could contribute to the 
understanding of the proneness to AMI in smokers, and to the best of our knowledge, this was 
the first report on this associations in humans. More resent publications have confirmed that 
MMP-9 levels are elevated in both previous (88) and current smokers (89). Heavy smoking 
has also been shown to increases MMP-9 gene expression in saphenous vein conduits (90). 
TIMP-1 levels were significantly lower in subjects with previously AMI, and might contribute 
to our hypothesis of the proneness to rupture of plaques by reduced inhibition of MMP-9, and 
thereby degrading of the fibrous cap. 
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8.3. Effects of long term diet and/or omega-3 fatty acids intervention  
One of the main findings in this study was no effect of intervention with n-3 PUFA and/or 
diet on levels of MMPs compared to controls. Conflicting results on this item have been 
reported. The results by Ercan et al. with diet intervention (91) are in accordance with our 
study, although with a shorter follow-up time of 2 months. Also in line with our results, a 
study of 12 weeks intervention with either 6.6 grams or 2.0 grams n-3 PUFA per day showed 
no significant changes in serum levels of MMP-9 or TIMP-1 (92). The latter dose is similar to 
the dosis used in our study. Others have shown reduction in MMP-9 levels in a short-term (3 
weeks) intervention with diet combined with exercise in patients with the metabolic 
syndrome, and thus to some degree comparable to our study population (70). 
We observed an overall correlation between the change in MMP-9/TIMP-1 ratio and the 
change in IMT, the latter being significantly influenced by dietary intervention (93). This 
might indicate the importance of MMP-9 for the progression of atherosclerosis, although no 
correlation with soluble MMP-9 could be detected. Our results are also partly in line with the 
study by Aarsetøy et al. (94), who found a non-significant reduction in MMP-9 in patients 
with AMI treated with n-3 PUFA supplementation for 12 months. However, they could 
demonstrate a significant increase in PAPP-A levels in their population with AMI, but only in 
subjects younger than 65 years, a population different from ours. It has been demonstrated 
in animal models, that n-3 PUFA exerts a beneficial effect on MMP-9, i.e. in accordance with 
our hypothesis (95). However, in our study, all groups showed significant reduction in MMPs 
after 3 years. The reduction in MMP-9, MMP-9/TIMP-1 ratio and PAPP-A during the study 
period might be explained by increased use of medications or higher age. Both statins and 
ACE-inhibitors have been shown to reduce MMP-9 levels (96), and in our population both 
medications were used in increased amounts throughout the study period. Previous studies 
have shown that statins inhibit secretion of MMPs (91;97) without affecting TIMP-1, possibly 
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contributing to the plaque-stabilizing effects of statins. However, we could not demonstrate 
lower levels of MMP-9 in statin users at baseline (Paper I). 
8.4. Importance for clinical cardiovascular outcome 
We investigated the hypothesis that an interaction between MMPs and plasma lipoproteins 
may be associated with cardiovascular risk. The 68 CV events recorded during the three-year 
study period were weakly associated with elevated MMP-9 levels compared to event-free 
subjects. This is to some degree in line with the results of Blankenberg et al. (98), showing a 
significant association with cardiovascular mortality. 
In our study, especially individuals in the upper quartile of MMP-9 had a significantly 
elevated risk for CV events, and even more pronounced risk when present in combination 
with hypertriglyceridaemia. Thus, the association between MMP-9 and CV events was partly 
dependent on high triglyceride values, despite no correlation between MMP-9 and 
triglycerides (Paper I). High triglyceride values in our study was defined as the upper quartile 
in the population, which is in accordance with the clinical definition of hypertriglyceridemia 
(1.7 mmol/L), thus this cut-off level should reflect a biological treshold.  The exact biological 
mechanism behind this interaction remains unknown, but hypertriglyceridaemia may 
introduce a proinflammatory state that contributes to the deleterious effect of MMP-9. MMP-
9 was strongly correlated to LDL-C as shown in Paper I, however, no further increase in event 
rate was observed with the combination of high MMP-9 and LDL-C levels, indicating VLDL-
cholesterol to be more important regarding this interaction.   
Our results indicate that MMP-9 might be a predictor in identifying elderly men at risk 
for CV events, also previously reported in another population (98). The non-independency 
shown in our study is in accordance with the study by Jeffris et al (99), showing MMP-9 to 
 45
predict clinical outcome in univariate analysis, however, not as a separate and independent 
predictor as adjustment for cigarette smoking attenuated the odds ratio.  
 
8.5. Time profiles of MMP-9, TIMPs and PAPP-A in STEMI and AP
The overall change in metalloproteinases and their inhibitors in the acute phase after AMI 
until 14 days, shown in Paper III, indicate that these markers are either involved in the process 
of the acute event per se or might only be solely markers of an acute phase reaction.  The PCI 
procedure per se seems to influence the variables to a limited degree. 
As we observed significantly lower levels of circulating MMP-9 in stable AP patients 
compared to AMI patients, it seems that the acute vs stable coronary syndrome correlates to 
the release of MMPs. This is in accordance with previous observations showing plaque 
rupture per se to be associated with increased MMP levels (100). MMP-9 is secreted from 
macrophages and is also released from T-lymphocytes, which is highly present in the ruptured 
plaque area and might therefore also be important sources for the MMP-9 obtained during an 
AMI (101;102). In addition, generation and secretion of MMP-9 have been shown when 
activated platelets adhere to the endothelium, an active process during an AMI (101). In 
animal models it has also been shown that MMP release occurs in the early phase after an 
acute MI (103). 
The role and regulation of TIMP-1 and -2, both synthesized by smooth muscle cells 
and macrophages, has not been established. Johnson and co-workers showed that 
overexpression of TIMP-2, but not TIMP-1, inhibits plaque development and destabilisation 
(105) which can be discussed along with our findings of TIMP-2 levels being higher in the 
AP-group compared to the AMI group throughout.  
Elevated PAPP-A levels have been suggested to predict ACS (106), and have also 
been shown to be a marker of plaque instability (107). The steep reduction observed in our 
 46
AMI-population from three hours to all later time points, support the notion that PAPP-A is 
an important marker, although the levels before PCI are unknown. Our results can also be 
discussed in line with a previous report showing an early peak in PAPP-A during the first 12 
hours from symptoms onset, followed by a rapid normalization after 48 hours (108). 
The limited changes in the stable AP patients indicate that the PCI-procedure itself does not 
induce release of MMP-9 and TIMP-1 and -2. Interestingly, we observed a significant rise in 
PAPP-A three hours after the procedure. PAPP-A is present in all human fibroblasts and is 
released during atherosclerotic plaque disruption, and therefore expected to be increased also 
in the AMI group. It might be speculated that the increase shown very early after PCI in the 
AP-group, is a result of procedure related release to the circulation from smooth muscle cells 
in the atherosclerotic plaque, which probably are masked in the AMI patients in which the 
levels before the procedure are unknown, but thought to be at a high level. It should, however, 
be emphasized that heparin induces release of PAPP-A (109;110), which may be relevant for 
the increase observed after 3 hours. The same heparinization procedure was, however, used in 
both groups, but the lack of increase in the AMI-group might be related to binding of heparin 
in the acute phase of an AMI (111).  
The early peak and thereafter a marked reduction in the MMP-9, MMP-9/TIMP-1 ratio and 
PAPP-A levels shown in the AMI group when compared to patients with stable AP, both 
treated with PCI, indicates that the metalloproteinases are involved in the early phase of the 
plaque rupture process, with limited influence of the PCI procedure.  
 
8.6. Effects of mBMC transplantation on MMPs in STEMI 
In this sub-study of ASTAMI limited influence of intracoronary injection of mBMC 
transplantation after AMI was observed on circulating levels of MMP-9, TIMP-1 and 
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EMMPRIN. There was, however, a more pronounced increase in MMP-9 after 2-3 weeks and 
3 months in the mBMC group. EMMPRIN levels were reduced during the study period in 
both groups.  
Our hypothesis in this part of the project was that treatment with mBMC would reduce 
the circulating levels of the selected biomarkers based on results from both in vitro and in vivo 
studies showing stem cell transplantation to reduce MMPs after AMI and also to improve 
ventricular remodeling (112). 
The underlying mechanisms for the influence of stem cells on MMPs are not clarified, and a 
conclusion regarding type of stem cells for the purpose of autologous transplantation has also 
not yet been made. In cell culture of cardiac fibroblasts Wang et al. (113) could demonstrate 
that the protein expression and activity of MMP-2, but not MMP-9, were increased in 
response to hypoxia, and decreased when co-cultured with mesenchymal stem cells. It has 
also been demonstrated that early endothelial progenitor cells increased MMP-9 expression in 
vitro, whereas MMP-2 was increased in outgrowth endothelial cells (114).  
As discussed in Paper IV, the type of stem cells seems to be of importance regarding the 
degree of influence on MMPs (115). A study on rat hearts with AMI, treatment with modified 
mesenchymal stem cells (116), showed a reduction in MMP-9 levels. The results can not be 
compared to ours, as mesenchymal stem cells are multipotent stromal cells with potential for 
differention into a variety of cell types (117). In this particular study the stem cell injection 
was performed only one hour after AMI compared to 5 days in our study, and the timing of 
the transplantation is still also a debatable question.  
We found a significantly more pronounced increase in MMP-9 levels in the mBMC 
group compared to controls, and in accordance with these findings, Roderfelt et al. 
demonstrated a transient inflammatory response and upregulation of MMP-9 activity after 
bone marrow transplantation in mice (118). As we previously have shown that MMP-9 levels 
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are reduced already 1 day after AMI (Paper III), we assume that the levels were normalized 
when baseline sampling in the this study was performed, and therefore limited influenced by 
the acute phase reaction.  
Studies have shown that invasive intervention principles to some extent affects the 
release of MMPs (119;120), although we found limited effects of the PCI-procedure per se 
(Paper III). Bone marrow aspiration was not performed in the control group in the ASTAMI 
study. This procedure which itself is a trauma, could influence the release of inflammatory 
markers and contribute to the elevated levels in the mBMC group. Accordingly, baseline 
measures which was performed before the stem cell aspiration, showed no significant 
differences between the groups. A similar mechanism might explain the increase in MMP-9 
levels shown in traumatic injury (121), and that elevated levels of MMP-9 may delay wound 
healing (122) and are associated with coronary artery in-stent restenosis (123). 
MMP-9 expression is a crucial pathogenic feature in a range of conditions and disease 
states, also other than CVD (124-126), in which treatment with stem cells have been shown to 
suppress or down regulate the MMP-9 expression (126) and thereby improving the current 
condition. The importance of EMMPRIN as an inducer of MMP-9 has been explored only to 
a limited extent in humans. In our study circulating levels of MMP-9 and EMMPRIN were 
significally correlated, indicating a common regulatory pathway. In the work by Reddy et al, 
both EMMPRIN and MMP-9 expression in primary cardiomyocytes were induced by the pro-
inflammatory cytokine interleukin-18. EMMPRIN was induced via JNK/Sp1 signalling and 
MMP-9 was induced both via EMMPRIN and through the transcription factors AP-1 and  
NF-NB activation (127). Other studies have shown a common inhibition of MMP-9 and 
EMMPRIN (128;129), and gene silencing of EMMPRIN was shown to reduce upregulation of 
MMP-9 in cell culture (130).  
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The significant reduction in genetic expression of MMP-9 seen at 3 months might be 
discussed as compensatory to the increase observed in the circulating levels. Circulating 
levels as well as genetic expression of EMMPRIN were significally reduced along with the 
increase in MMP-9 which might be discussed as a negative feed back mechanism. Expression 
of the EMMPRIN-gene in circulating leukocytes, also reported by Xu et al. assessed by flow 
cytometry (131), may indicate that the leukocytes contribute to the circulating levels, although 
no correlation between circulating levels and gene expression levels was observed in our 
study. The reduction over time seen in EMMPRIN expression, with subsequent reduction in 
MMP-9 gene expression, contribute to the assumption that EMMPRIN is an inducer of  
MMP-9.  
 
8.7. Association between the measured biomarkers and myocardial injury and 
infarct size  
In Paper III, no significant correlations between MMP-9, TIMP-1/2 and PAPP-A and infarct 
injury measured by troponin T and CK-MB, or infarct size measured by MRI were found. 
This is in accordance with others (104), and may be discussed to be due to the relatively small 
infarcts in the population studied. 
In the ASTAMI population (Paper IV), we observed significant correlations between 
both MMP-9 and EMMPRIN, and myocardial injury assessed by biomarkers (CK) as well as 
by infarct size measured by SPECT. In this population the infarcts were larger, which may 
explain the different results. In experimental AMI, MMP-9 has been shown to increase infarct 
size and left ventricular fibrosis (20), in accordance with our findings. As for EMMPRIN, this 
has been sparsely explored in humans, however, it has been shown that EMMPRIN is 
enhanced in cardiomyopathies and therefore proposed as a marker for cardiac inflammation 
(132). We also observed an inverse correlation between EMMPRIN and LVEF. An 
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association between EMMPRIN and the degree of myocardial injury and LVEF was also 
reported in the work by Nie et al (133), but this was a post mortem immunohistochemistry 
study which showed a strong increase in EMMPRIN around the zone of necrosis in the AMI 
group. As to our knowlegde, such association has not previously been reported in clinical 
studies with survivers after myocardial infarction. Our results contributes to the suggestion 
that the expression of EMMPRIN is a decisive factor in regulating MMP-9 activity, and 
thereby being involved in myocardial remodeling. 
 
MMP-9, and also EMMPRIN as an inducer of MMP-9 have in several contexts been 
discussed to be ‘bad guys’, thus an attempt to reduce such levels would be beneficial.  In our 
work focusing atherosclerosis and CHD, intervention with diet, marine n-3 PUFA, or 
transplantation with autologous bone marrow stem cells, failed to reduce the circulating levels 
or gene expression of our selected markers in our populations of human subjects.  
The anti-TNF-D antibodies infliximab and etanercept have been shown to reduce the serum 
levels and expression of MMP-9 (134;135) in human subjects with rheumatoid arthritis, and 
also in an animal model. A future goal in preventing atherosclerosis and its serious 
complications, therefore, might be in line with these results, with more pin pointed influence 
on the inflammatory process
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9. Conclusions 
In the present work on matrix metalloproteinases, aimed to investigate any importance of the 
MMPs in atherosclerosis and coronary heart disease, we could demonstrate:  
- a highly significant correlation between MMP-9 and serum lipids, elevated MMP-9 
levels in smokers, and reduced TIMP-1 levels in subjects with previous AMI  
- individuals with high levels of MMP-9 had a significantly higher risk of 
cardiovascular events, especially in combination with hypertriglyceridaemia 
-  intervention with diet and/or n-3 PUFA supplementation for 3 years did not influence 
the levels of MMP-9, TIMP-1 or PAPP-A  
- patients with ST-elevation myocardial infarction treated with PCI, presented initially 
with high levels of MMP-9, followed by an early reduction of both MMP-9, MMP-
9/TIMP-1 ratio and PAPP-A, compared to patients with stable angina pectoris treated 
with the same procedure  
- limited effects of intracoronary injection of mBMC transplantation on circulating 
levels as well as gene expression of MMP-9 and EMMPRIN in patients with STEMI 
treated with PCI 
- both MMP-9 and EMMPRIN, were significantly correlated to myocardial injury and 
infarct size in STEMI patients with larger infarcts, indicating that the regulation of 
metalloproteinases is important in the process of an AMI. 
 
Interventions with diet, n-3 PUFA or autologous bone marrow stem cell transplantation did 
not influence the levels of the selected matrix metalloproteinases in our populations.  
Nevertheless, these results might strengthen the hypothesis that metalloproteinases are 
involved in atherosclerosis, and might be useful tools in identifying individuals at risk for 
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cardiovascular events. Furthermore, the results contribute to the understanding of the 
pathophysiology of metalloproteinases in AMI, but in the treatment with autologous bone 
marrow stem cells, further investigations are needed regarding influence of timing and type of 
cells. 
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